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Objective—To determine if Chlamydia trachomatis (Ct) seropositivity as detected by the Ct 
elementary body (EB)-based enzyme linked immunosorbent assay (Ct EB ELISA) predicts 
pregnancy and pregnancy outcome among infertile women with documented tubal patency.
Design—Cohort study
Setting—Outpatient clinics participating in the reproductive medicine network
Patients—1250 infertile women with documented tubal patency enrolled in one of two 
randomized controlled trials: PPCOSII and AMIGOS
Intervention—Sera were analyzed for anti-Ct IgG1 and IgG3 antibodies using a research Ct EB 
ELISA. OD405 readings ≥0.35 and ≥0.1 were considered positive for IgG1 and IgG3, respectively.
Main Outcome Measures—Primary outcomes included pregnancy, live birth, and ectopic 
pregnancy. Log linear regression was used to determine the relative risk after adjusting for age, 
race, treatment medication, smoking status, and current alcohol use.
Results—243 (19%) women were seropositive for anti-Ct IgG3. They tended to be non-White 
and smokers. Anti-Ct IgG3 seropositive women were significantly less likely to conceive (RR 
0.65, 95% CI 0.52-0.83) or to have a live birth (RR 0.59, 95% 0.43-0.80); these associations were 
weakened after adjusting for number of HSG-documented patent tubes (RR 0.73, 95% CI 
0.56-0.97) and (0.73, 95% CI: 0.50-1.04), respectively. Anti-Ct IgG3 seropositive women who 
conceived had 2.7 (95% CI: 1.40-5.34) times the risk of ectopic pregnancy.
Conclusions—Even in the presence of tubal patency, anti-Ct IgG3 seropositivity is associated 
with lower likelihood of pregnancy. Anti-Ct IgG3 seropositive women have up to 3 times the risk 
of ectopic pregnancy.
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Introduction
Ascending Chlamydial trachomatis (Ct) infection induces inflammation, damage to the 
ciliated cells of the fallopian tubes, and pelvic adhesion formation. Furthermore, untreated 
upper genital tract infections can lead to irrevocable damage to the fallopian tubes including 
proximal and distal tubal occlusion and the formation of hydrosalpinges. This can lead to 
sterility if both fallopian tubes are affected. Tubal and peritoneal pathologies are the most 
common causes of infertility, affecting approximately 30-35% of couples (1). Symptomatic 
upper genital tract infections are diagnosed clinically as pelvic inflammatory disease. The 
risk of tubal factor infertility following one episode of pelvic inflammatory disease is 
approximately 10-12%; risk increases with recurrent episodes (2).
Previous exposure to Ct can be determined by assessing serostatus for anti-Ct 
immunoglobulin G (Ct IgG). A variety of immunoassays have been utilized for the detection 
of Ct IgG, including the micro-immunofluorescent antibody assay, enzyme immunoassay, 
and immunofluorescent assay. Commonly results are reported as titers (Ct titer, CTT). While 
the cut-off value for the titer that defines seropositivity varies, previous studies suggest that 
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CTT is a sensitive screening test for bilateral tubal obstruction among women with infertility 
(3-11).
The specificity of commercial assays is limited by their cross-reactivity to Chlamydia 
pneumoniae. However, more specific assays are in development. In 2012 Geisler et al. used 
a sensitive and specific Ct elementary body-based enzyme linked immunosorbent assay (EB 
ELISA) to demonstrate that IgG1 and IgG3 comprise the predominant serum anti-Ct 
antibody response; seropositivity appeared to be sustained for 6 months (12). In their study 
of 98 patients with current chlamydial infections, 73% tested seropositive using the 
commercially available Ct- IgG-ELISA plus Medac (Medac, Germany), compared with 90% 
seropositivity with the EB ELISA.
Given the prior observed relationship between CTT and tubal disease, and the development 
of an assay that appears to be superior in the detection of prior infection, we sought to 
examine the relationship between Ct seropositivity and outcomes following non-ART 
treatment for non-tubal factor infertility. Specifically we sought to determine if Ct 
seropositivity as detected by the Ct EB ELISA predicts pregnancy and pregnancy outcome 
among infertile women with documented tubal patency. Were this hypothesis to be 
confirmed, we would infer the value of screening infertile women to identify those at risk 
for poor reproductive outcomes despite tubal patency.
Materials and Methods
This is a cohort study of 1251 women enrolled in two trials conducted by the NICHD 
Cooperative Reproductive Medicine Network: PPCOS II and AMIGOS. PPCOS II was a 
randomized controlled trial comparing clomiphene citrate and letrozole for the treatment of 
infertility due to polycystic ovarian syndrome. AMIGOS was a randomized controlled trial 
comparing treatment with gonadotropins, clomiphene citrate, or letrozole in conjunction 
with intrauterine insemination in the treatment of unexplained infertility. Inclusion and 
exclusion criteria have been previously published (13, 14). In both trials women were 
between the ages of 18 and 40. Male partners had a screening semen analysis with at least 
14 million sperm per milliliter (PPCOS II) or 5 million sperm per milliter (AMIGOS) with 
documented motility. Tubal patency was documented by one of the three following criteria: 
1) a hysterosalpingogram or laparoscopy showing at least one patent fallopian tube; 2) saline 
infusion sonography showing accumulation of fluid in the cul-de-sac; or 3) prior 
uncomplicated intrauterine pregnancy resulting in live birth in the preceding 3 years (8 
women or <1% of subjects). Women enrolled in AMIGOS were also required to be regularly 
ovulating. In both trials women provided a blood sample at baseline prior to treatment. 
Consent was requested of all participants for storage and use of deidentified samples for 
future research. IRB approval was obtained for both trials.
Women enrolled in PPCOS II (N=750) were randomized to up to 5 cycles of medications 
and were instructed to have regular intercourse. Women enrolled in AMIGOS (N=900) were 
randomized to up to 4 cycles of medications followed by intrauterine insemination. 
Pregnancy was detected by serum human chorionic gonadotropin levels, followed by 
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transvaginal ultrasound between 6 and 9 weeks to document fetal viability. Pregnancy 
outcomes were confirmed by a review of medical records.
Of the 1650 women enrolled in the two trials, 1251 consented for use of residual samples for 
future research. Serum was tested at the University of Alabama at Birmingham for anti-CT 
IgG1 and IgG3 antibodies using a Ct EB ELISA by reported methods (12). The optical 
density (OD) of reactions was measured at 405nm (OD405) and cut-off values for positive 
IgG1 and IgG3 were ≥0.35 and ≥0.1, respectively. The reported serological responses 
represent the mean of triplicate determinations of 1/32 diluted serum.
Outcomes of interest for this study included conception, ectopic pregnancy, and live birth. 
Conception was defined as a rising serum level of human chorionic gonadotropin on two 
consecutive tests (AMIGOS) or a serum level of human chorionic gonadotropin of more 
than 10 mIU per milliliter (PPCOS II).
Chi square analyses were used to compare each outcome (conception, ectopic pregnancy 
[among those that conceived], and live birth) by Ct seropositivity for IgG1, IgG3, and IgG1 
or IgG3. Preliminary analyses suggested the strongest relationship with the primary 
outcomes and anti-Ct IgG3 serostatus. For this reason, bivariate analyses including t-test, chi 
square analyses, and Fischer exact tests were performed, where appropriate, to assess the 
relationship between other covariates and anti-Ct IgG3 serostatus. Subsequently log-
binomial regression models were created to determine the independent association between 
anti-Ct IgG3 serostatus and each outcome as measured by relative risk with 95% confidence 
intervals. Initially all potential confounders were included in the model but subsequently 
covariates that did not change the point estimate by more than 10% were removed from the 
model to achieve a more parsimonious model. STATA 13.0 (College Station, Texas) was 
used for all analyses.
Results
Ct serostatus results were obtained in 1250 (>99%) of the samples. 243 (19%) were 
seropositive for IgG3, 331 (26%) for IgG1, 397 (32%) for either IgG1 or IgG3, and 177 
(14%) for both. 449 (36%) of participants conceived, 311 (25%) had a live birth, and 23 
(2%) had an ectopic pregnancy.
Bivariate analyses for anti-Ct IgG subclasses and each outcome are presented in Table 1. Ct 
seropositivity for either IgG1 or IgG3 was inversely associated with conception and the 
probability of live birth. However, only Ct seropositivity for IgG3 was a significant 
predictor of both failure to conceive and ectopic pregnancy. 26% of women who were 
seropositive for IgG3 conceived, while 38% of women seronegative for IgG3 conceived 
(p<0.001). Women seropositive for IgG3 had an 11% incidence of ectopic pregnancy, while 
those that were seronegative had a 4% incidence (p=0.02).
Subsequent bivariate analyses were conducted to determine predictors of IgG3 
seropositivity. Women who were seropositive for IgG3 were more likely to be younger, non-
Caucasian, lower-educated, and obese than women who were seronegative for IgG3 (Table 
2).
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Multivariate analyses evaluating the independent associations between anti Ct-IgG3 
seropositivity and probability of pregnancy, live birth, and ectopic pregnancy are presented 
in Table 3. After adjusting for age, race, treatment medication (gonadotropins, clomid, or 
letrozole), smoking status, and current alcohol use, women who were seropositive for IgG3 
were significantly less likely to conceive (RR 0.65, 95% CI 0.52-0.83) or to have a live birth 
(RR 0.59, 95% 0.43-0.80); these associations were weakened after adjusting for the number 
of confirmed patent tubes (RR 0.73, 95% CI 0.56-0.97) and (0.73, 95% CI: 0.50-1.04), 
respectively. Women, who conceived and were Ct seropositive had a 2.7 (95% CI: 
1.40-5.34) fold increase in the risk of ectopic pregnancy.
Discussion
In this study, we found that Ct seropositivity decreases the probability of pregnancy and live 
birth and increases the risk of ectopic pregnancy in infertile women with documented tubal 
patency. Of the two IgG subclasses examined, anti-Ct IgG3 serostatus was most strongly 
associated with all three outcomes. Ct seropositivity was more commonly observed in 
women with other risk factors for infertility such as smoking and obesity. However, the 
associations between anti-Ct IgG3 seropositivity and all reproductive outcomes remained 
after adjusting for these potential confounders.
In this study of women with documented tubal patency receiving non-ART treatment for 
infertility, Ct seropositivity lowered the probability of conceiving by 35%. In a study by 
Coppus et al, Ct serostatus was assessed using a microimmunofluorescence assay or ELISA 
(15). 1882 women with documented bilateral tubal patency were followed for up to 12 
months and pregnancy, but not live birth, was determined. 23% of subjects were 
seropositive. Seropositive subjects had a 35% reduction in fecundability. Although the 
current study differs by choice of assay and inclusion criteria for tubal patency, the findings 
are similar. Prior studies had conflicting results (6, 9, 11, 16, 17). However, in general, these 
studies were underpowered, included treatment dependent and independent pregnancies, 
and/or were case-control study designs.
In this study, we evaluated Ct serostatus based on detection of the IgG subclasses IgG1 and 
IgG3 using the EB ELISA as IgG1 and IgG3 comprise the predominant anti-Ct serum 
antibody responses (12). Women, who were Ct seropositive by IgG3 showed the greatest 
reduction in probability of pregnancy and live birth. It is believed that IgG3 is involved in 
early response to infection and then is short-lived with IgG1 emerging as the major effector 
in clearing infection (18). The detection of IgG3 in these women could represent either 
recent Ct infection that has cleared or alternatively persisting infection. In either instance, 
detection of anti-Ct IgG3 may reflect more recent inflammatory damage to the fallopian 
tube, contributing to the pregnancy difficulties but perhaps not of sufficient duration or 
severity to lead to blockage of the fallopian tubes.
Further supporting our suggestion that Ct seropositivity may well represent undiagnosed 
tubal/peritoneal disease is our observation that seropositive women who conceived had 
almost three times the risk of ectopic pregnancy. Normal migration of the fertilized oocyte 
from the ampulla of the oviduct into the uterine cavity is dependent on contractions of the 
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tubal musculature, ciliary activity, and the flow of tubal secretions (19). Rhythmic oviduct 
contractions are due to a network of pacemaker like interstitial cells in conjunction with 
smooth muscle cells. A recent study showed that this pacemaker cell network is disrupted 
with Ct infections resulting in loss of normal oviduct contractile activity (20). Ct infections 
may also inhibit normal oviduct ciliary activity or ciliary beat frequency (21) and increase 
secretions, further inhibiting normal progression. Thus tubal pathology may be present even 
in the setting of normal appearing, patent fallopian tubes.
This study has some weaknesses. First it is a secondary analysis. Second, the criteria for 
documentation of tubal patency were not strict; however, they are likely consistent with 
clinical practice. Women did receive treatment, thus, we cannot necessarily generalize these 
results to those women attempting to conceive naturally. We can also not differentiate 
diagnosis effects from insemination effects. All women with PCOS had timed intercourse, 
while women with unexplained infertility received intrauterine insemination. However, none 
of the women received in vitro fertilization, thus pregnancy was still dependent on in vivo 
fertilization. While study (PPCOS II versus AMIGOS) did differ in prevalence of 
seropositivity, the study was not related to the probability of achieving a pregnancy. Thus, 
study did not act as a confounder. After adding study to the model, the effect estimates did 
not change significantly (pregnancy: RR 0.64 vs. RR 0.65; live birth RR 0.59 vs. RR 0.59). 
For a more parsimonious model, we therefore did not include this covariate in the model for 
the multivariate analysis. Finally the cohort is comprised of participants in two studies with 
different study populations; however, many of the inclusion, exclusion, and outcomes 
measures had been intentionally harmonized to allow for such combined analyses.
The study has many strengths. First, this study is adequately powered. Although an a priori 
power calculation was not conducted, a post hoc power analysis revealed that this study had 
80% power to detect a 9% difference in live birth rates, given Ct seroprevalence of 20%. 
Second the cohort is well characterized. Third, this is one of the few studies that has live 
birth as the primary outcome. Finally, we used an assay that has been shown to be more 
sensitive than the commercial assay Medac in the detection of Ct seropositivity. In addition 
to being highly sensitive and specific, the Ct EB ELISA provided the opportunity to assess 
the relationship of IgG subclass to the different reproductive outcomes.
In conclusion, women who are Ct seropositive by IgG3 have a significantly lower chance of 
conceiving in the setting of documented tubal patency. This may be due to underlying 
damage to fallopian tubal architecture. Future screening for tubal factor infertility may 
include both an assessment of anti-Ct IgG3 seropositivity and a radiologic evaluation 
(hysterosalpingography or saline infusion sonography) for documenting tubal patency. Ct 
seropositivity would potentially identify those with tubal pathology and at risk for ectopic 
pregnancy.
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Table 1
Incidence of pregnancy, live birth, and ectopic pregnancy by Chlamydia trachomatis IgG1 and IgG3 
serostatus.
Pregnant Live birth Ectopic
IgG1 or IgG3
 Seropositive (N=397) 128 (32%) 84 (21%) 10 (8%)
 Seronegative (N=853) 321 (38%) 227 (27%) 13 (4%)
 P-value 0.06 0.04 0.10
IgG1
 Seropositive (N=331) 107 (32%) 68 (21%) 8 (7%)
 Seronegative (N=919) 342 (37%) 243 (26%) 15 (4%)
 P-value 0.11 0.03 0.21
IgG3
 Seropositive (N=243) 62 (26%) 39 (16%) 7 (11%)
 Seronegative (N=1007) 387 (38%) 272 (27%) 16 (4%)
 P-value <0.001 <0.001 0.02













Steiner et al. Page 10
Table 2
Patient characteristics by Chlamydia trachomatis IgG3 serostatus
Ct Seronegative 1007 (81%) Ct Seropositive 243 (19%) P-value
Age (years) 0.02
 18-26 166 (16%) 55 (23%)
 27-31 400 (40%) 100 (41%)
 32-34 223 (22%) 35 (14%)
 35-41 218 (22%) 53 (22%)
Race <0.001
 Caucasian 890 (88%) 165 (68%)
 Other 117 (12%) 78 (32%)
Education level <0.001
 High school or earlier 126 (13%) 56 (23%)
 Some college 256 (25%) 96 (40%)
 College degree 413 (41%) 59 (24%)
 Graduate degree 212 (21%) 32 (13%)
Nulligravid 608 (60%) 156 (64%) 0.27
Current smoker 92 (9%) 42 (17%) <0.001
Current alcohol use 703 (70%) 179 (74%) 0.24
Body mass index (kg/m2) 0.001
 < 18.5 15 (1%) 4 (2%)
 18.5-24.9 362 (36%) 54 (22%)
 25-29.9 221 (22%) 61 (25%)
 ≥30 409 (41%) 124 (51%)
Study 0.004
 PPCOS II 399 (40%) 121 (50%)
 AMIGOS 609 (60%) 122 (50%)
Treatment 0.35
 Clomiphene 401 (40%) 102 (42%)
 Letrozole 403 (40%) 102 (42%)
 Gonadotropins 203 (20%) 39 (16%)
Number of documented patent tubes 0.06
 At least 1 289 (29%) 87 (36%)
 1 86 (8%) 28 (11%)
 2 632 (63%) 128 (53%)
a
Fisher's exact test
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Table 3
Independent association between IgG3 Chlamydia trahomatis seropositivity and pregnancy, live birth, and 
ectopic pregnancy.
Model 1 Model 2
RR 95% CI RR 95% CI
Pregnancy 0.65 0.52-0.83 0.73 0.56-0.97
Live birth 0.59 0.43-0.80 0.73 0.50-1.04
Ectopic 2.7 1.40-5.34
Model 1: adjusts for age, race, treatment medication, current smoker, current alcohol use
Model 2: adjusts for age, race, treatment medication, current smoker, current alcohol use and number of confirmed patent tubes
Fertil Steril. Author manuscript; available in PMC 2016 December 01.
